SkinBioTherapeutics plc (AIM:SBTX)

London flag London · Delayed Price · Currency is GBP · Price in GBX
8.00
+0.25 (3.23%)
At close: Feb 27, 2026
-60.20%
Market Cap 20.73M
Revenue (ttm) 4.64M
Net Income (ttm) -696.25K
Shares Out 259.17M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,901,537
Average Volume 10,527,388
Open 7.75
Previous Close 7.75
Day's Range 7.50 - 8.50
52-Week Range 5.00 - 27.50
Beta 0.73
RSI 31.67
Earnings Date Mar 25, 2026

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 41
Stock Exchange London Stock Exchange AIM
Ticker Symbol SBTX
Full Company Profile

Financial Performance

In fiscal year 2025, SkinBioTherapeutics's revenue was 4.64 million, an increase of 283.74% compared to the previous year's 1.21 million. Losses were -696,253, -75.79% less than in 2024.

Financial Statements

News

There is no news available yet.